Risk stratification of pediatric AML is mostly based on cytogenetics; however, some recurrent mutations such as NPM1, CEBPA, and FLT3-ITD with WT1 are also included in most risk classifications.41 This evidence concerns the gene NPM1 and acute myeloid leukemia.